1
|
Gos M, Cebula J, Goszczyński TM. Metallacarboranes in Medicinal Chemistry: Current Advances and Future Perspectives. J Med Chem 2024; 67:8481-8501. [PMID: 38769934 DOI: 10.1021/acs.jmedchem.4c00157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2024]
Abstract
Metallacarboranes, exemplified by cobalt bis(dicarbollide) ([COSAN]-), have excelled their historical metallocene analogue label to become promising in drug design, medical studies, and fundamental biological research. Serving as a unique platform for conjugation with biomolecules, they also constitute an auspicious building block for biologically active derivatives and a carrier for cellular transport of membrane-impermeable cargos. Modified [COSAN]- exhibits specific antimicrobial, antiviral, and anticancer actions showing promise for preclinical trials. Contributing to the ongoing development in medicinal chemistry, metallacarboranes offer desirable physicochemical properties and low acute toxicity. This article presents a critical look at metallacarboranes in the context of their application in medicinal chemistry, emphasizing [COSAN]- as a potential game-changer in drug design and biomedical sciences. As medicinal chemistry seeks innovative building blocks, metallacarboranes emerge as an important novelty with versatile solutions and promising implications.
Collapse
Affiliation(s)
- Michalina Gos
- Laboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
| | - Jakub Cebula
- Laboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
| | - Tomasz M Goszczyński
- Laboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
| |
Collapse
|
2
|
Kawasaki R, Oshige A, Yamana K, Hirano H, Nishimura K, Miura Y, Yorioka R, Sanada Y, Bando K, Tabata A, Yasuhara K, Miyazaki Y, Shinoda W, Nishimura T, Azuma H, Takata T, Sakurai Y, Tanaka H, Suzuki M, Nagasaki T, Ikeda A. HER-2-Targeted Boron Neutron Capture Therapy with Carborane-integrated Immunoliposomes Prepared via an Exchanging Reaction. Chemistry 2023; 29:e202302486. [PMID: 37792507 DOI: 10.1002/chem.202302486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 09/09/2023] [Accepted: 10/04/2023] [Indexed: 10/06/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising modality for cancer treatment because of its minimal invasiveness. To maximize the therapeutic benefits of BNCT, the development of efficient platforms for the delivery of boron agents is indispensable. Here, carborane-integrated immunoliposomes were prepared via an exchanging reaction to achieve HER-2-targeted BNCT. The conjugation of an anti-HER-2 antibody to carborane-integrated liposomes successfully endowed these liposomes with targeting properties toward HER-2-overexpressing human ovarian cancer cells (SK-OV3); the resulting BNCT activity toward SK-OV3 cells obtained using the current immunoliposomal system was 14-fold that of the l-BPA/fructose complex, which is a clinically available boron agent. Moreover, the growth of spheroids treated with this system followed by thermal neutron irradiation was significantly suppressed compared with treatment with the l-BPA/fructose complex.
Collapse
Affiliation(s)
- Riku Kawasaki
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| | - Ayano Oshige
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| | - Keita Yamana
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| | - Hidetoshi Hirano
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| | - Kotaro Nishimura
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| | - Yamato Miura
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| | - Ryuji Yorioka
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| | - Yu Sanada
- Institute for Integrated Radiation and Nuclear Science, Kyoto University Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Kaori Bando
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka city, 558-8585, Japan
| | - Anri Tabata
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka city, 558-8585, Japan
| | - Kazuma Yasuhara
- Division of Materials Science, Graduate School of Science and Technology and Center for Digital Green-Innovation, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma, Nara, 630-0192, Japan
| | - Yusuke Miyazaki
- Research Institute for Interdisciplinary Science, Okayama University, 3-1-1 Tsushuma-naka, Kita-ku, Okayama, 700-8530, Japan
| | - Wataru Shinoda
- Research Institute for Interdisciplinary Science, Okayama University, 3-1-1 Tsushuma-naka, Kita-ku, Okayama, 700-8530, Japan
| | - Tomoki Nishimura
- Department of Chemistry and Materials, Faculty of Textile Science and Technology, Shinshu University, Ueda, 386-8567, Japan
| | - Hideki Azuma
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka city, 558-8585, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Takeshi Nagasaki
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka city, 558-8585, Japan
| | - Atsushi Ikeda
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, 739-8527, Japan
| |
Collapse
|
3
|
Coghi P, Li J, Hosmane NS, Zhu Y. Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment. Med Res Rev 2023; 43:1809-1830. [PMID: 37102375 DOI: 10.1002/med.21964] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 03/27/2023] [Accepted: 04/12/2023] [Indexed: 04/28/2023]
Abstract
Boron neutron capture therapy (BNCT) is one of the most promising treatments among neutron capture therapies due to its long-term clinical application and unequivocally obtained success during clinical trials. Boron drug and neutron play an equivalent crucial role in BNCT. Nevertheless, current clinically used l-boronophenylalanine (BPA) and sodium borocaptate (BSH) suffer from large uptake dose and low blood to tumor selectivity, and that initiated overwhelm screening of next generation of BNCT agents. Various boron agents, such as small molecules and macro/nano-vehicles, have been explored with better success. In this featured article, different types of agents are rationally analyzed and compared, and the feasible targets are shared to present a perspective view for the future of BNCT in cancer treatment. This review aims at summarizing the current knowledge of a variety of boron compounds, reported recently, for the application of BCNT.
Collapse
Affiliation(s)
- Paolo Coghi
- School of Pharmacy, Macau University of Science and Technology, Macau, China
| | - Jinxin Li
- School of Pharmacy, Macau University of Science and Technology, Macau, China
| | - Narayan S Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois, USA
| | | |
Collapse
|
4
|
Ailuno G, Balboni A, Caviglioli G, Lai F, Barbieri F, Dellacasagrande I, Florio T, Baldassari S. Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment. Cells 2022; 11:cells11244029. [PMID: 36552793 PMCID: PMC9776957 DOI: 10.3390/cells11244029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 12/09/2022] [Accepted: 12/11/2022] [Indexed: 12/15/2022] Open
Abstract
Boron neutron capture therapy is a low-invasive cancer therapy based on the neutron fission process that occurs upon thermal neutron irradiation of 10B-containing compounds; this process causes the release of alpha particles that selectively damage cancer cells. Although several clinical studies involving mercaptoundecahydro-closo-dodecaborate and the boronophenylalanine-fructose complex are currently ongoing, the success of this promising anticancer therapy is hampered by the lack of appropriate drug delivery systems to selectively carry therapeutic concentrations of boron atoms to cancer tissues, allowing prolonged boron retention therein and avoiding the damage of healthy tissues. To achieve these goals, numerous research groups have explored the possibility to formulate nanoparticulate systems for boron delivery. In this review. we report the newest developments on boron vehiculating drug delivery systems based on nanoparticles, distinguished on the basis of the type of carrier used, with a specific focus on the formulation aspects.
Collapse
Affiliation(s)
- Giorgia Ailuno
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Alice Balboni
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| | | | - Francesco Lai
- Department of Life and Environmental Sciences (DiSVA), University of Cagliari, 09124 Cagliari, Italy
| | - Federica Barbieri
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
| | | | - Tullio Florio
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
- IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Sara Baldassari
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| |
Collapse
|
5
|
Cheng X, Li F, Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress. Curr Oncol 2022; 29:7868-7886. [PMID: 36290899 PMCID: PMC9601095 DOI: 10.3390/curroncol29100622] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 10/11/2022] [Accepted: 10/13/2022] [Indexed: 11/05/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (10B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles and recoil 7Li nuclei (10B [n, α] 7Li). Therefore, the most important part in BNCT is to selectively deliver a large number of 10B to tumor cells and only a small amount to normal tissue. So far, BNCT has been used in more than 2000 cases worldwide, and the efficacy of BNCT in the treatment of head and neck cancer, malignant meningioma, melanoma and hepatocellular carcinoma has been confirmed. We collected and collated clinical studies of second-generation boron delivery agents. The combination of different drugs, the mode of administration, and the combination of multiple treatments have an important impact on patient survival. We summarized the critical issues that must be addressed, with the hope that the next generation of boron delivery agents will overcome these challenges.
Collapse
Affiliation(s)
- Xiang Cheng
- Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China
| | - Fanfan Li
- Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China
- Correspondence: (F.L.); (L.L.); Tel.: +86-13855137365 (F.L.); +86-15905602477 (L.L.)
| | - Lizhen Liang
- Hefei Comprehensive National Science Center, Institute of Energy, Building 9, Binhu Excellence City Phase I, 16 Huayuan Avenue, Baohe District, Hefei 230031, China
- Correspondence: (F.L.); (L.L.); Tel.: +86-13855137365 (F.L.); +86-15905602477 (L.L.)
| |
Collapse
|
6
|
Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun 2022; 13:2143. [PMID: 35440126 PMCID: PMC9018847 DOI: 10.1038/s41467-022-29780-w] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 03/31/2022] [Indexed: 11/08/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is an attractive approach to treat invasive malignant tumours due to binary heavy-particle irradiation, but its clinical applications have been hindered by boron delivery agents with low in vivo stability, poor biocompatibility, and limited application of combinational modalities. Here, we report boronsome, a carboranyl-phosphatidylcholine based liposome for combinational BNCT and chemotherapy. Theoretical simulations and experimental approaches illustrate high stability of boronsome. Then positron emission tomography (PET) imaging with Cu-64 labelled boronsome reveals high-specific tumour accumulation and long retention with a clear irradiation background. In particular, we show the suppression of tumour growth treated with boronsome with neutron irradiation and therapeutic outcomes are further improved by encapsulation of chemotherapy drugs, especially with PARP1 inhibitors. In sum, boronsome may be an efficient agent for concurrent chemoradiotherapy with theranostic properties against malignancies. Boron neutron capture therapy is a type of cancer therapy but is associated with insufficient boron delivery and with poor biocompatibility. Here, the authors constructed boronated lipids to generate - boronsome - and show the system can reduce tumour growth.
Collapse
|
7
|
Zaboronok A, Khaptakhanova P, Uspenskii S, Bekarevich R, Mechetina L, Volkova O, Mathis BJ, Kanygin V, Ishikawa E, Kasatova A, Kasatov D, Shchudlo I, Sycheva T, Taskaev S, Matsumura A. Polymer-Stabilized Elemental Boron Nanoparticles for Boron Neutron Capture Therapy: Initial Irradiation Experiments. Pharmaceutics 2022; 14:pharmaceutics14040761. [PMID: 35456595 PMCID: PMC9032815 DOI: 10.3390/pharmaceutics14040761] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 03/29/2022] [Accepted: 03/29/2022] [Indexed: 01/24/2023] Open
Abstract
Sufficient boron-10 isotope (10B) accumulation by tumor cells is one of the main requirements for successful boron neutron capture therapy (BNCT). The inability of the clinically registered 10B-containing borophenylalanine (BPA) to maintain a high boron tumor concentration during neutron irradiation after a single injection has been partially solved by its continuous infusion; however, its lack of persistence has driven the development of new compounds that overcome the imperfections of BPA. We propose using elemental boron nanoparticles (eBNPs) synthesized by cascade ultrasonic dispersion and destruction of elemental boron microparticles and stabilized with hydroxyethylcellulose (HEC) as a core component of a novel boron drug for BNCT. These HEC particles are stable in aqueous media and show no apparent influence on U251, U87, and T98G human glioma cell proliferation without neutron beam irradiation. In BNCT experiments, cells incubated with eBNPs or BPA at an equivalent concentration of 40 µg 10B/mL for 24 h or control cells without boron were irradiated at an accelerator-based neutron source with a total fluence of thermal and epithermal neutrons of 2.685, 5.370, or 8.055 × 1012/cm2. The eBNPs significantly reduced colony-forming capacity in all studied cells during BNCT compared to BPA, verified by cell-survival curves fit to the linear-quadratic model and calculated radiobiological parameters, though the effect of both compounds differed depending on the cell line. The results of our study warrant further tumor targeting-oriented modifications of synthesized nanoparticles and subsequent in vivo BNCT experiments.
Collapse
Affiliation(s)
- Alexander Zaboronok
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (E.I.); (A.M.)
- Laboratory of Medical and Biological Problems of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Street, 630090 Novosibirsk, Russia;
- Correspondence: ; Tel.: +81-29-853-3220; Fax: +81-29-853-3214
| | - Polina Khaptakhanova
- Enikolopov Institute of Synthetic Polymeric Materials, Russian Academy of Sciences, 70, Profsoyuznaya Street, 117393 Moscow, Russia; (P.K.); (S.U.)
| | - Sergey Uspenskii
- Enikolopov Institute of Synthetic Polymeric Materials, Russian Academy of Sciences, 70, Profsoyuznaya Street, 117393 Moscow, Russia; (P.K.); (S.U.)
| | - Raman Bekarevich
- The Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), Advanced Microscopy Laboratory, Trinity College Dublin, The University of Dublin, D02 W272 Dublin, Ireland;
- Research Center for Advanced Measurement and Characterization, National Institute for Materials Science, 1-2-1 Sengen, Tsukuba 305-0047, Japan
| | - Ludmila Mechetina
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Novosibirsk, 8/2 Lavrentieva, 630090 Novosibirsk, Russia; (L.M.); (O.V.)
| | - Olga Volkova
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Novosibirsk, 8/2 Lavrentieva, 630090 Novosibirsk, Russia; (L.M.); (O.V.)
| | - Bryan J. Mathis
- International Medical Center, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba 305-8576, Japan;
| | - Vladimir Kanygin
- Laboratory of Medical and Biological Problems of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Street, 630090 Novosibirsk, Russia;
| | - Eiichi Ishikawa
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (E.I.); (A.M.)
| | - Anna Kasatova
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, 11 Lavrentieva, 630090 Novosibirsk, Russia; (A.K.); (D.K.); (I.S.); (T.S.); (S.T.)
- Laboratory of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Street, 630090 Novosibirsk, Russia
| | - Dmitrii Kasatov
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, 11 Lavrentieva, 630090 Novosibirsk, Russia; (A.K.); (D.K.); (I.S.); (T.S.); (S.T.)
- Laboratory of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Street, 630090 Novosibirsk, Russia
| | - Ivan Shchudlo
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, 11 Lavrentieva, 630090 Novosibirsk, Russia; (A.K.); (D.K.); (I.S.); (T.S.); (S.T.)
- Laboratory of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Street, 630090 Novosibirsk, Russia
| | - Tatiana Sycheva
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, 11 Lavrentieva, 630090 Novosibirsk, Russia; (A.K.); (D.K.); (I.S.); (T.S.); (S.T.)
- Laboratory of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Street, 630090 Novosibirsk, Russia
| | - Sergey Taskaev
- Budker Institute of Nuclear Physics, Siberian Branch of Russian Academy of Sciences, 11 Lavrentieva, 630090 Novosibirsk, Russia; (A.K.); (D.K.); (I.S.); (T.S.); (S.T.)
- Laboratory of BNCT, Department of Physics, Novosibirsk State University, 1 Pirogov Street, 630090 Novosibirsk, Russia
| | - Akira Matsumura
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan; (E.I.); (A.M.)
| |
Collapse
|
8
|
Ueda H, Suzuki M, Sakurai Y, Tanaka T, Aoki S. Design, Synthesis and Biological Evaluation of Boron‐Containing Macrocyclic Polyamine Dimers and Their Zinc(II) Complexes for Boron Neutron Capture Therapy. Eur J Inorg Chem 2022. [DOI: 10.1002/ejic.202100949] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Hiroki Ueda
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science Kyoto University 2-Asashiro-nishi, Kumatori Osaka 590-0494 Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science Kyoto University 2-Asashiro-nishi, Kumatori Osaka 590-0494 Japan
| | - Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
- Research Institute for Science and Technology Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
- Research Institute for Biomedical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| |
Collapse
|
9
|
Alhallak K, Sun J, Muz B, Jeske A, Yavner J, Bash H, Park C, Lubben B, Adebayo O, Achilefu S, DiPersio JF, Azab AK. Nanoparticle T cell engagers for the treatment of acute myeloid leukemia. Oncotarget 2021; 12:1878-1885. [PMID: 34548905 PMCID: PMC8448516 DOI: 10.18632/oncotarget.28054] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Accepted: 08/13/2021] [Indexed: 12/11/2022] Open
Abstract
Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%. The standard-of-care for AML has not changed in the past few decades. Promising immunotherapy options are being developed for the treatment of AML; yet, these regimens require highly laborious and sophisticated techniques. We create nanoTCEs using liposomes conjugated to monoclonal antibodies to enable specific binding. We also recreate the bone marrow niche using our 3D culture system and use immunocompromised mice to enable use of human AML and T cells with nanoTCEs. We show that CD33 is ubiquitously present on AML cells. The CD33 nanoTCEs bind preferentially to AML cells compared to Isotype. We show that nanoTCEs effectively activate T cells and induce AML killing in vitro and in vivo. Our findings suggest that our nanoTCE technology is a novel and promising immuno-therapy for the treatment of AML and provides a basis for supplemental investigations for the validation of using nanoTCEs in larger animals and patients.
Collapse
Affiliation(s)
- Kinan Alhallak
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.,Department of Biomedical Engineering, Washington University McKelvey School of Engineering, St. Louis, MO 63130, USA
| | - Jennifer Sun
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.,Department of Biomedical Engineering, Washington University McKelvey School of Engineering, St. Louis, MO 63130, USA
| | - Barbara Muz
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Amanda Jeske
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Jessica Yavner
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Hannah Bash
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Chaelee Park
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Berit Lubben
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Ola Adebayo
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Samuel Achilefu
- Department of Biomedical Engineering, Washington University McKelvey School of Engineering, St. Louis, MO 63130, USA.,Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - John F DiPersio
- Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Abdel Kareem Azab
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.,Department of Biomedical Engineering, Washington University McKelvey School of Engineering, St. Louis, MO 63130, USA
| |
Collapse
|
10
|
Ueda H, Suzuki M, Kuroda R, Tanaka T, Aoki S. Design, Synthesis, and Biological Evaluation of Boron-Containing Macrocyclic Polyamines and Their Zinc(II) Complexes for Boron Neutron Capture Therapy. J Med Chem 2021; 64:8523-8544. [PMID: 34077212 PMCID: PMC8279495 DOI: 10.1021/acs.jmedchem.1c00445] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Boron neutron capture therapy (BNCT)
is a binary therapeutic method
for cancer treatment based on the use of a combination of a cancer-specific
drug containing boron-10 (10B) and thermal neutron irradiation.
For successful BNCT, 10B-containing molecules need to accumulate
specifically in cancer cells, because destructive effect of the generated
heavy particles is limited basically to boron-containing cells. Herein,
we report on the design and synthesis of boron compounds that are
functionalized with 9-, 12-, and 15-membered macrocyclic polyamines
and their Zn2+ complexes. Their cytotoxicity, intracellular
uptake activity into cancer cells and normal cells, and BNCT effect
are also reported. The experimental data suggest that mono- and/or
diprotonated forms of metal-free [12]aneN4- and [15]aneN5-type ligands are uptaken into cancer cells, and their complexes
with intracellular metals such as Zn2+ would induce cell
death upon thermal neutron irradiation, possibly via interactions
with DNA.
Collapse
Affiliation(s)
- Hiroki Ueda
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-nishi, Kumatori, Osaka 590-0494, Japan
| | - Reiko Kuroda
- Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.,Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.,Research Institute for Biomedical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| |
Collapse
|
11
|
Zhao M, Feng W, Li C, Xiu W, Li M, Liu S, Wang L, Huang W, Zhao Q. A photothermally-induced HClO-releasing nanoplatform for imaging-guided tumor ablation and bacterial prevention. Biomater Sci 2021; 8:7145-7153. [PMID: 33151202 DOI: 10.1039/d0bm01629b] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Photothermal therapy (PTT) is a cure that can inhibit tumor growth effectively and even remove tumor via photo-induced local hyperthermia. However, its shortcoming lies in the fact that excessive heat is most likely to lead to thermal injury at the epidermis of the tumor region and even the area of the surrounding tissue. As a consequence, the exposure of the thermally-induced wound would result in the increased risk of bacterial infection. To date, few PTT platforms have attached importance to the prevention of bacterial infection at the photothermally-induced wound. Herein, we reported a thermally-sensitive liposome nanosystem (Lipo-B-TCCA) containing aza-BODIPY and trichloroisocyanuric acid, which is conductive for the PTT of tumor and the prevention of bacteria. It is observed that the designed nanoplatform could exhibit remarkable stability, high photothermal conversion efficiency (31.4%), and efficient HClO-releasing ability in vitro and in vivo. Moreover, Lipo-B-TCCA is able to eliminate tumor efficiently via near infrared fluorescence and photothermal imaging guidance with low side effects. Most importantly, Lipo-B-TCCA could prevent the growth of S. aureus in the thermal wound during the process of PTT. The imaging-guided photothermally-induced HClO-releasing PTT nanoplatform for tumor ablation and bacterial prevention shows excellent performance and great potential for biomedical applications.
Collapse
Affiliation(s)
- Menglong Zhao
- Key Laboratory for Organic Electronics and Information Displays & Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, 9 Wenyuan Road, Nanjing 210023, P. R. China.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Feiner IVJ, Pulagam KR, Uribe KB, Passannante R, Simó C, Zamacola K, Gómez-Vallejo V, Herrero-Álvarez N, Cossío U, Baz Z, Caffarel MM, Lawrie CH, Vugts DJ, Rejc L, Llop J. Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy. J Mater Chem B 2021; 9:410-420. [PMID: 33367431 DOI: 10.1039/d0tb01880e] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer treatment exploiting the neutron capture capacity and subsequent fission reaction of boron-10. The emergence of nanotechnology has encouraged the development of nanocarriers capable of accumulating boron atoms preferentially in tumour cells. However, a long circulation time, required for high tumour accumulation, is usually accompanied by accumulation of the nanosystem in organs such as the liver and the spleen, which may cause off-target side effects. This could be overcome by using small-sized boron carriers via a pre-targeting strategy. Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. Enhanced tumour accumulation was achieved when using a pretargeting approach, which was accomplished by a highly selective biorthogonal reaction at the tumour site with trans-cyclooctene-functionalised Trastuzumab.
Collapse
Affiliation(s)
- Irene V J Feiner
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Krishna R Pulagam
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Kepa B Uribe
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Rossana Passannante
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Cristina Simó
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Kepa Zamacola
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Vanessa Gómez-Vallejo
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | | | - Unai Cossío
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - Zuriñe Baz
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
| | - María M Caffarel
- Biodonostia Health Research Institute, San Sebastian, Spain and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| | - Charles H Lawrie
- Biodonostia Health Research Institute, San Sebastian, Spain and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain and Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Danielle J Vugts
- Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. Radiology & Nuclear Medicine, The Netherlands
| | - Luka Rejc
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. and University of Ljubljana, Faculty of Chemistry and Chemical Technology, Večna pot 113, 1000 Ljubljana, Slovenia
| | - Jordi Llop
- CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. and Centro de Investigación Biomédica en Red, Enfermedades Respiratorias - CIBERES, Madrid, Spain
| |
Collapse
|
13
|
Chan WJ, Cho HL, Goudar V, Bupphathong S, Shu CH, Kung C, Tseng FG. Boron-enriched polyvinyl-alcohol/boric-acid nanoparticles for boron neutron capture therapy. Nanomedicine (Lond) 2021; 16:441-452. [DOI: 10.2217/nnm-2020-0401] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background: Due to the noninvasive nature of boron neutron capture therapy (BNCT), it is considered a promising cancer treatment method. Aim: To investigate whether polyvinyl alcohol/boric acid crosslinked nanoparticles (PVA/BA NPs) are an efficient delivery system for BNCT. Materials & methods: PVA/BA NPs were synthesized and cocultured with brain and oral cancers cells for BNCT. Results: PVA/BA NPs had a boron-loading capacity of 7.83 ± 1.75 w/w%. They accumulated in brain and oral cancers cells at least threefold more than in fibroblasts and macrophages. The IC50 values of the brain and oral cancers cells were at least ninefold and sixfold lower than those of fibroblasts and macrophages, respectively. Conclusion: Theoretically, PVA/BA NPs target brain and oral cancers cells and could offer improved therapeutic outcomes of BNCT.
Collapse
Affiliation(s)
- Wei-Jen Chan
- Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Han-Lin Cho
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Venkanagouda Goudar
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Sasinan Bupphathong
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Chi-Hung Shu
- Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Chi Kung
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Fan-Gang Tseng
- Engineering & System Science, National Tsing Hua University, Hsinchu 30013, Taiwan
- Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan
- Research Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan
| |
Collapse
|
14
|
Wróblewska A, Szermer-Olearnik B, Pajtasz-Piasecka E. Nanocząstki o wysokiej zawartości boru
jako potencjalne nośniki w terapii
borowo-neutronowej. POSTEP HIG MED DOSW 2021. [DOI: 10.5604/01.3001.0014.7760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Podstawą terapii borowo-neutronowej (boron neutron capture therapy, BNCT) jest selektywne
dostarczenie boru do komórek nowotworowych, a następnie napromienienie zmienionego
chorobowo miejsca wiązką neutronów. W wyniku tego procesu dochodzi do rozszczepienia
jądra izotopu 10B, co powoduje uwolnienie energii niszczącej komórki nowotworowe.
Mimo że badania związane z BNCT trwają od lat 50. XX wieku, pozostaje ona wciąż terapią
eksperymentalną. Jest to związane m.in. z brakiem nośników umożliwiających szybkie i skuteczne
wprowadzanie 10B do środowiska nowotworu. Tak więc często podnoszonym zagadnieniem
i jednym z głównych wyzwań dla rozwoju BNCT, jest poszukiwanie selektywnych
związków dostarczających wymaganą ilość tego pierwiastka. Istotnym aspektem są badania
nad nanometrycznymi strukturami, takimi jak liposomy zawierające związki bogate w bor
lub nieorganiczne nanocząstki – węglik boru czy azotek boru. Ze względu na dużą zawartość
boru oraz możliwość modyfikacji powierzchni tych nanocząstek, mogą się one okazać
wyjątkowo atrakcyjnym narzędziem w celowanej BNCT. Równie ważnym problemem tej terapii
jest opracowanie precyzyjnych powiązań między źródłem neutronów, specyfiką wiązki
a rodzajem zastosowanego nośnika. W artykule wskazujemy na wysoki potencjał związków
bogatych w bor jako nośników w celowanej terapii borowo-neutronowej.
Collapse
Affiliation(s)
- Anna Wróblewska
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| | - Bożena Szermer-Olearnik
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| | - Elżbieta Pajtasz-Piasecka
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| |
Collapse
|
15
|
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia 2021; 35:2346-2357. [PMID: 33479469 PMCID: PMC8292428 DOI: 10.1038/s41375-021-01127-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 12/01/2020] [Accepted: 01/07/2021] [Indexed: 01/29/2023]
Abstract
T-cell-based immunotherapy, such as CAR-T cells and bispecific T-cell engagers (BiTEs), has shown promising clinical outcomes in many cancers; however, these therapies have significant limitations, such as poor pharmacokinetics and the ability to target only one antigen on the cancer cells. In multiclonal diseases, these therapies confer the development of antigen-less clones, causing tumor escape and relapse. In this study, we developed nanoparticle-based bispecific T-cell engagers (nanoBiTEs), which are liposomes decorated with anti-CD3 monoclonal antibodies (mAbs) targeting T cells, and mAbs targeting the cancer antigen. We also developed a nanoparticle that targets multiple cancer antigens by conjugating multiple mAbs against multiple cancer antigens for T-cell engagement (nanoMuTEs). NanoBiTEs and nanoMuTEs have a long half-life of about 60 h, which enables once-a-week administration instead of continuous infusion, while maintaining efficacy in vitro and in vivo. NanoMuTEs targeting multiple cancer antigens showed greater efficacy in myeloma cells in vitro and in vivo, compared to nanoBiTEs targeting only one cancer antigen. Unlike nanoBiTEs, treatment with nanoMuTEs did not cause downregulation (or loss) of a single antigen, and prevented the development of antigen-less tumor escape. Our nanoparticle-based immuno-engaging technology provides a solution for the major limitations of current immunotherapy technologies.
Collapse
|
16
|
Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun 2020; 11:6037. [PMID: 33247158 PMCID: PMC7699624 DOI: 10.1038/s41467-020-19932-1] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Accepted: 10/23/2020] [Indexed: 12/21/2022] Open
Abstract
Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major role in drug resistance in MM. Drug delivery with targeted nanoparticles have been shown to improve specificity and efficacy and reduce toxicity. We aim to improve treatments for MM by (1) using nanoparticle delivery to enhance efficacy and reduce toxicity; (2) targeting the tumor-associated endothelium for specific delivery of the cargo to the tumor area, and (3) synchronizing the delivery of chemotherapy (bortezomib; BTZ) and BMME-disrupting agents (ROCK inhibitor) to overcome BMME-induced drug resistance. We find that targeting the BMME with P-selectin glycoprotein ligand-1 (PSGL-1)-targeted BTZ and ROCK inhibitor-loaded liposomes is more effective than free drugs, non-targeted liposomes, and single-agent controls and reduces severe BTZ-associated side effects. These results support the use of PSGL-1-targeted multi-drug and even non-targeted liposomal BTZ formulations for the enhancement of patient outcome in MM.
Collapse
Affiliation(s)
- Cinzia Federico
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Kinan Alhallak
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Jennifer Sun
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Kathleen Duncan
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Feda Azab
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Gail P Sudlow
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Pilar de la Puente
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Barbara Muz
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Vaishali Kapoor
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Luna Zhang
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Fangzheng Yuan
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA
| | - Matea Markovic
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA
| | - Joseph Kotsybar
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA
| | - Katherine Wasden
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Nicole Guenthner
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Shannon Gurley
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Justin King
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
| | - Daniel Kohnen
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
| | - Noha N Salama
- Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Dinesh Thotala
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Dennis E Hallahan
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Ravi Vij
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
| | - John F DiPersio
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
| | - Samuel Achilefu
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Abdel Kareem Azab
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA.
| |
Collapse
|
17
|
In Vitro and In Vivo Evaluation of Fluorescently Labeled Borocaptate-Containing Liposomes. J Fluoresc 2020; 31:73-83. [PMID: 33078252 DOI: 10.1007/s10895-020-02637-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Accepted: 10/14/2020] [Indexed: 10/23/2022]
Abstract
Boron neutron capture therapy (BNCT), a binary cancer therapeutic modality, has moved to a new phase since development of accelerator-based neutron sources and establishment of BNCT centers in Finland and Japan. That stimulated efforts for better boron delivery agent development. As liposomes have shown effective boron delivery properties and sufficient tumor retention, fluorescent liposome labelling may serve as a rapid method to study initial ability of newly synthesized liposomes to be captured by tumor cells prior to experiments on boron accumulation and neutron irradiation. In this work, we studied the accumulation and biodistribution of pegylated liposomes with encapsulated borocaptate (BSH) and a fluorescent label (Nile Red) in U87 (human glioblastoma), SW-620 (human colon carcinoma), SK-MEL-28 (human melanoma), FetMSC (mesenchymal human embryo stem cells), and EMBR (primary embryocytes) cell lines as well as an orthotopic xenograft model of U87 glioma in SCID mice. Results indicate that fluorescent microscopy is effective at determining the intracellular localization of the liposomes using a fluorescent label. The synthesized, pegylated liposomes showed higher accumulation in tumors compared to normal cells, with characteristic concentration peaks in SW-620 and U87 cell lines, and provided in vivo tumor selectivity with several-fold higher tumor tissue fluorescence at the 6-h timepoint. Graphical abstract Fluorescent images of U-87 glioma cells after 24 hours of incubation with BSH-containing liposomes labeled with lipophilic Nile Red (red color)and water-soluble FITC-Dextran (green color); cell nuclei in blue color (DAPI-staining) (×400). Scale bar is 50 μm. Fluorescent labelling serves as anexpress method to study liposome delivery efficiency prior to boron accumulation evaluation and BNCT irradiation experiments.
Collapse
|
18
|
Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: Current status and future perspectives. Cancer Commun (Lond) 2020; 40:406-421. [PMID: 32805063 PMCID: PMC7494062 DOI: 10.1002/cac2.12089] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 06/09/2020] [Accepted: 08/09/2020] [Indexed: 12/11/2022] Open
Abstract
The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.
Collapse
Affiliation(s)
- Mayya Alexandrovna Dymova
- Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 8, Novosibirsk, 630090, Russia
| | - Sergey Yurjevich Taskaev
- Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 11, Novosibirsk, 630090, Russia.,Laboratory of Boron Neutron Capture Therapy, Novosibirsk State University, Pirogova str. 1, Novosibirsk, 630090, Russia
| | - Vladimir Alexandrovich Richter
- Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 8, Novosibirsk, 630090, Russia
| | - Elena Vladimirovna Kuligina
- Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentjeva Av. 8, Novosibirsk, 630090, Russia
| |
Collapse
|
19
|
Hiller NDJ, do Amaral e Silva NA, Tavares TA, Faria RX, Eberlin MN, de Luna Martins D. Arylboronic Acids and their Myriad of Applications Beyond Organic Synthesis. European J Org Chem 2020. [DOI: 10.1002/ejoc.202000396] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Noemi de Jesus Hiller
- Instituto de Química; Laboratório de Catálise e Síntese (Lab CSI); Laboratório 413; Universidade Federal Fluminense; Outeiro de São João Batista s/n; Campus do Valonguinho, Centro Niterói RJ 24020-141 Brasil
| | - Nayane Abreu do Amaral e Silva
- Instituto de Química; Laboratório de Catálise e Síntese (Lab CSI); Laboratório 413; Universidade Federal Fluminense; Outeiro de São João Batista s/n; Campus do Valonguinho, Centro Niterói RJ 24020-141 Brasil
| | - Thais Apolinário Tavares
- Instituto de Química; Laboratório de Catálise e Síntese (Lab CSI); Laboratório 413; Universidade Federal Fluminense; Outeiro de São João Batista s/n; Campus do Valonguinho, Centro Niterói RJ 24020-141 Brasil
| | - Robson Xavier Faria
- Laboratório de Toxoplasmose e outras Protozooses; Instituto Oswaldo Cruz, Fiocruz; Av. Brasil, 4365 Manguinhos Rio de Janeiro RJ 21040-360 Brasil
| | - Marcos Nogueira Eberlin
- Mackenzie Presbyterian University; School of Engineering; Rua da Consolação, 930 SP 01302-907 São Paulo Brasil
| | - Daniela de Luna Martins
- Instituto de Química; Laboratório de Catálise e Síntese (Lab CSI); Laboratório 413; Universidade Federal Fluminense; Outeiro de São João Batista s/n; Campus do Valonguinho, Centro Niterói RJ 24020-141 Brasil
| |
Collapse
|
20
|
Zavjalov E, Zaboronok A, Kanygin V, Kasatova A, Kichigin A, Mukhamadiyarov R, Razumov I, Sycheva T, Mathis BJ, Maezono SEB, Matsumura A, Taskaev S. Accelerator-based boron neutron capture therapy for malignant glioma: a pilot neutron irradiation study using boron phenylalanine, sodium borocaptate and liposomal borocaptate with a heterotopic U87 glioblastoma model in SCID mice. Int J Radiat Biol 2020; 96:868-878. [PMID: 32339057 DOI: 10.1080/09553002.2020.1761039] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Purpose: To evaluate the efficacy of boron neutron capture therapy (BNCT) for a heterotopic U87 glioblastoma model in SCID mice using boron phenylalanine (BPA), sodium borocaptate (BSH) and liposomal BSH as boron compounds at a unique, accelerator-based neutron source.Materials and methods: Glioblastoma models were obtained by subcutaneous implantation of U87 cells in the right thighs of SCID mice before administration of 350 mg/kg of BPA (BPA-group), 100 mg/kg of BSH (BSH-group) or 100 mg/kg of BSH in PEGylated liposomes (liposomal BSH-group) into the retroorbital sinus. Liposomes were prepared by reverse-phase evaporation. Neutron irradiation was carried out at a proton accelerator with a lithium target developed for BNCT at the Budker Institute of Nuclear Physics, Novosibirsk, Russian Federation. A proton beam current integral of 3 mA/h and energy of 2.05 MeV were used for neutron generation.Results: Boron compound accumulation in tumor tissues at the beginning of irradiation was higher in the BPA group, followed by the Liposomal BSH and BSH groups. Tumor growth was significantly slower in all irradiated mice from the 7th day after BNCT compared to untreated controls (p < .05). Tumor growth in all treated groups showed no large variation, apart from the Irradiation only group and the BPA group on the 7th day after BNCT. The overall trend of tumor growth was clear and the differences between treatment groups became significant from the 50th day after BNCT. Tumor growth was significantly slower in the Liposomal BSH group compared to the Irradiation only group on the 50th (p = .012), 53rd (p = .005), and the 57th (p = .021) days after treatment. Tumor growth in the Liposomal BSH group was significantly different from that in the BPA group on the 53rd day after BNCT (p = .021) and in the BSH group on the 50th (p = .024), 53rd (p = .015), and 57th (p = .038) days after BNCT. Skin reactions in the form of erosions and ulcers in the tumor area developed in treated as well as untreated animals with further formation of fistulas and necrotic decay cavities in most irradiated mice.Conclusions: We observed a tendency of BNCT at the accelerator-based neutron source to reduce or suspend the growth of human glioblastoma in immunodeficient animals. Liposomal BSH showed better long-term results compared to BPA and non-liposomal BSH. Further modifications in liposomal boron delivery are being studied to improve treatment outcomes.
Collapse
Affiliation(s)
- Evgenii Zavjalov
- Laboratory of medical and biological problems of BNCT, Novosibirsk State University, Novosibirsk, Russia.,Center for Genetic Resources of Laboratory Animals, Institute of Cytology and Genetics SB RAS, Novosibirsk, Russia
| | - Alexander Zaboronok
- Laboratory of medical and biological problems of BNCT, Novosibirsk State University, Novosibirsk, Russia.,Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Vladimir Kanygin
- Laboratory of medical and biological problems of BNCT, Novosibirsk State University, Novosibirsk, Russia
| | - Anna Kasatova
- Laboratory of medical and biological problems of BNCT, Novosibirsk State University, Novosibirsk, Russia.,Budker Institute of Nuclear Physics, Novosibirsk, Russia
| | - Aleksandr Kichigin
- Laboratory of medical and biological problems of BNCT, Novosibirsk State University, Novosibirsk, Russia
| | - Rinat Mukhamadiyarov
- Laboratory of medical and biological problems of BNCT, Novosibirsk State University, Novosibirsk, Russia.,Research Institute for Complex Issues of Cardiovascular Diseases SB RAS, Kemerovo, Russia
| | - Ivan Razumov
- Laboratory of medical and biological problems of BNCT, Novosibirsk State University, Novosibirsk, Russia.,Center for Genetic Resources of Laboratory Animals, Institute of Cytology and Genetics SB RAS, Novosibirsk, Russia
| | | | - Bryan J Mathis
- Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Sakura Eri B Maezono
- PhD Program in Human Biology, School of Integrative and Global Majors and International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Akira Matsumura
- Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Sergey Taskaev
- Budker Institute of Nuclear Physics, Novosibirsk, Russia.,Laboratory of BNCT, Novosibirsk State University, Novosibirsk, Russia
| |
Collapse
|